HC Wainwright Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

HC Wainwright began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report released on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $65.00 price target on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ Q1 2024 earnings at ($1.43) EPS, Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.41) EPS, Q4 2024 earnings at ($1.56) EPS, FY2024 earnings at ($5.75) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.28) EPS and FY2028 earnings at ($6.25) EPS.

A number of other equities analysts have also commented on JSPR. Oppenheimer restated an outperform rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Evercore ISI began coverage on shares of Jasper Therapeutics in a research note on Wednesday, April 3rd. They issued an outperform rating and a $65.00 price objective on the stock. TD Cowen initiated coverage on Jasper Therapeutics in a research note on Monday, March 18th. They set an outperform rating for the company. Finally, Royal Bank of Canada assumed coverage on Jasper Therapeutics in a research note on Thursday, March 28th. They issued an outperform rating and a $70.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics currently has an average rating of Buy and an average price target of $64.29.

Jasper Therapeutics Trading Down 6.9 %

NASDAQ:JSPR opened at $21.19 on Monday. The stock has a 50 day simple moving average of $25.52 and a 200 day simple moving average of $15.08. The stock has a market cap of $319.12 million, a P/E ratio of -3.42 and a beta of 2.25. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.15. As a group, sell-side analysts forecast that Jasper Therapeutics will post -5 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently modified their holdings of JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at about $3,144,000. Kingdon Capital Management L.L.C. lifted its position in shares of Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares during the period. Fernwood Investment Management LLC boosted its stake in Jasper Therapeutics by 8.8% during the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after acquiring an additional 40,000 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in Jasper Therapeutics in the fourth quarter worth $197,000. Finally, Cowen AND Company LLC bought a new stake in Jasper Therapeutics in the third quarter valued at $140,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.